Nov 6, 2026 · 2h 13m
AI’s market reckoning meets jobs, robotics and biotech’s next phase
AI Boom Reality Check, Jobs Boom, Cybertruck Scrapped | Praveer Melwani, Keller Cliffton, Rahul Sonwalkar, Max Siegelman, D.A. Wallach
The episode tests whether AI’s market correction reflects temporary investor pressure or a deeper reset in technology, labor, and drug discovery.
- 1AI valuations face a sharper test as sell-offs, leverage, and a possible Anthropic IPO reshape investor expectations.
- 2Autonomous delivery and robotics are moving from ambitious demos toward factories, retail rollouts, and city-scale deployment.
- 3Biotech’s AI opportunity depends less on model novelty than on biological data, software infrastructure, and clinical regulation.
Don't miss
D.A. Wallach explains why AI’s promise in drug discovery still runs into the hardest constraint: proving safety and efficacy in human trials.
The brief
John and Jordi open with an AI-led technology sell-off, a possible Anthropic IPO, hedge-fund losses, and the question of whether falling prices signal opportunity or excess.
The market debate widens into a reality check on the economy: strong jobs data, manufacturing employment, leverage, and the difficulty of sustaining high growth while investor sentiment turns.
The Cybertruck’s weak sales and production wind-down contrast with electric hypercars, autonomous delivery, and a broader shift from conspicuous hardware toward software-driven mobility.
Praveer Melwani, Keller Cliffton, and Rahul Sonwalkar explain how Figma, Zipline, and Julius AI are turning AI into workflows, delivery networks, and demanding finance benchmarks.
Max Siegelman discusses building a luxury brand through scarcity and community, while D.A. Wallach connects music, biotech investing, biological data, China, and the limits of human trials.
The episode’s central tension is whether AI can accelerate real-world systems—from laboratories to drug discovery—without outrunning the data, economics, and regulation that make them trustworthy.
What was said on this episode
37 statements · 20 positive · 9 negative · 1 mixed · 7 neutral
Tech stocks lost $2.5 trillion in market value during a historic sell-off.
“Wall Street got a $2.5 trillion reality check with historic route of tech stocks.”
Listen at 1:34
Anthropic may offer investors a substantial discount after the AI sell-off.
“if you liked this company in summer, you should love it now because you potentially are going to get in at a massive discount”
Listen at 9:24
The U.S. added 165,000 jobs in October.
“165,000 jobs added in October.”
Listen at 17:38
The U.S. currently has a strong job market supporting the economy.
“strong job market. Good place to be in for the U.S. economy.”
Listen at 18:08
A coyote became the first documented animal to use the Wallace Annenberg Wildlife Crossing.
“a coyote has become the first documented animal to use the Wallace Annenberg Wildlife Crossing over the 101 freeway.”
Listen at 24:24
The Cybertruck’s build quality is poor.
“The build quality is, is really bad.”
Listen at 28:22
The Yangwang U9 Extreme costs approximately $3 million.
“this is a $3 million car, I guess.”
Listen at 34:21
Wave-pool technology is improving rapidly enough to make older pools less enjoyable.
“the pools that i was surfing two years ago are not fun anymore in comparison to the pool that i just surfed”
Listen at 43:23
- Keller Clifftonon autonomous delivery technologyNegative1:05:28
Autonomous delivery technology proved harder to develop than expected.
“the technology wound up being harder than people were expecting.”
Listen at 1:05:28
- Rahul Sonwalkaron Julius AI Deep Finance benchmarkNeutral1:12:17
Julius AI’s Deep Finance benchmark evaluates models on real investment-banking and private-equity deals.
“the goal is to see how good models do on real world big deals that you would see in investment banking and private equity.”
Listen at 1:12:17
- Rahul Sonwalkaron Inkling 2 SmallPositive1:17:40
Inkling 2 Small ranked as the best American and second-best overall open-source model.
“we found that it's actually the best American open source model and second best open source model overall after Kimmy.”
Listen at 1:17:40
Siegelman Stable is a contemporary luxury fashion brand based in New York.
“we're a contemporary luxury fashion brand based in New York.”
Listen at 1:20:23
Siegelman Stable is pursuing a long-term luxury-brand strategy rather than rapid monetization.
“it's the long play for us. And it's a business decision.”
Listen at 1:28:16
Siegelman Stable uses paid media at very small scale mainly for brand awareness.
“We do it at a very, very small scale, but a lot of it is awareness.”
Listen at 1:31:42
GLP-1 drugs are the first blockbuster preventive medicine.
“GLP-1 is the first blockbuster preventative medicine.”
Listen at 1:49:31
GLP-1 drugs will reduce risk factors for other major diseases.
“it's going to reduce all the other risk factors for the other diseases that get us.”
Listen at 1:49:38
Several cancers have become curable diseases over the past decade.
“in the past decade, a number of cancers are now curable diseases.”
Listen at 1:50:45
Human testing remains necessary to establish drug safety and effectiveness.
“The only way to find out if things are safe and effective is in a human world.”
Listen at 1:53:20
AI will almost certainly generate better drug-development ideas.
“I think we almost certainly will get better ideas.”
Listen at 1:53:46
AI may gradually reduce average drug-development time from 12 years toward 10 years.
“maybe a drug's development time goes from 12 years to 11 years and then maybe to 10 years.”
Listen at 1:55:42
AI will not cure cancer or solve aging overnight; such claims are sales pitches.
“But is it going to cure cancer overnight? Is it going to solve aging overnight? Those are sales pitches.”
Listen at 1:56:08
Sustained rising interest rates generally create difficult conditions for biotech.
“when you're in a secularly rising rate environment in general, tough for biotech.”
Listen at 1:56:46
AI labs are becoming prospective buyers of biological datasets.
“the AI labs are prospective buyers of biological data sets.”
Listen at 1:58:55
China’s rise is a larger shift for biopharma than AI.
“In a way, a bigger shift than AI, the biopharma industry, is the rise of China.”
Listen at 2:02:27
China has sought to perform preclinical biopharma work at roughly one-quarter the U.S. cost.
“In China, what they have tried to do is all of that work at a quarter of the price.”
Listen at 2:03:19
Multinational pharmaceutical companies increasingly conduct preclinical work in China.
“increasingly they've been comfortable doing that work in China.”
Listen at 2:03:31
Chinese preclinical biopharma work is of outstanding quality.
“the quality of the work is outstanding”
Listen at 2:03:38
China’s AI strategy is to make AI free, cheap, and good for broad business adoption.
“China's strategy is make AI free, cheap, and good so that every business person in China can use it and outcompete whoever else around the world wants to give a run at some thing.”
Listen at 2:05:55
The U.S. is directing substantial venture capital toward ambitious biotech problems.
“we're throwing crazy venture money at these like millennium problems”
Listen at 2:06:08
Big pharma has achieved substantial manufacturing-process yield increases.
“big pharma has already seen a lot of yield increase when it comes to manufacturing process”
Listen at 2:08:09
The FDA plays an important global role because it is trusted on drug safety.
“The United States FDA plays a really important function globally because everyone trusts us. to be hard asses about drug safety.”
Listen at 2:09:58
The FDA effectively protects patients and supports trust in medicines.
“the FDA, I think does a really nice job. keeping patients safe, making sure we trust the medicines we're getting.”
Listen at 2:10:28
FDA drug approval requires evidence of both safety and effectiveness.
“for the FDA to approve a drug, they've got to believe that the company has proven it is both safe. And effective.”
Listen at 2:10:51
Many compounded peptides may be unsafe or ineffective, and probably are.
“there are a lot of people out there buying peptides from compounding pharmacies that may not be safe, that may not be effective, probably aren't.”
Listen at 2:11:17
Peptide products are highly complicated.
“the bottom line is this stuff is really complicated”
Listen at 2:11:48
Peptide products are potentially dangerous.
“I think it's kind of dangerous, right?”
Listen at 2:12:32
Many peptide products are ineffective or fraudulent snake oil.
“peptides are, in many cases, snake oil.”
Listen at 2:12:47
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Books & mentions
Some links are affiliate links — PodLume may earn a commission if you buy.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.